The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs

Christopher J Murphy, Ellison Bentley, Paul E. Miller, Kim McIntyre, Gary Leatherberry, Richard Dubielzig, Elizabeth Giuliano, Cecil P. Moore, Thomas E. Phillips, Peter B. Smith, Elizabeth Prescott, Jacqueline M. Miller, Peter Thomas, Randall Scagliotti, Doug Esson, Tom Gadek, Charles A. O'Neill

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Purpose. Keratoconjunctivitis sicca (KCS) is characterized by inflammation and decreased production of tears containing increased levels of cytokines. The release occurs in the setting of conjunctival and lacrimal gland inflammation, potentially mediated by the interaction between lymphocyte function- associated antigen (LFA)-1, a cell surface protein found on lymphocytes, and its cognate ligand intercellular adhesion molecule (ICAM)-1. SAR 1118 is a novel LFA-1 antagonist and may be an effective therapeutic agent for the treatment of KCS. The following studies were performed to assess the in vitro activity of SAR 1118 and to evaluate the clinical efficacy of topical SAR 1118 for the treatment of idiopathic canine KCS. Method. Pharmacodynamics were assessed by measuring the ability of SAR 1118 to inhibit Jurkat T-cell binding with recombinant human ICAM-1 and to inhibit cytokine release from human peripheral blood mononuclear cells (PBMCs) stimulated by staphylococcal enterotoxin B. For the assessment of clinical efficacy, 10 dogs diagnosed with idiopathic KCS were treated with SAR 1118 1% topical ophthalmic solution three times daily for 12 weeks. Schirmer's tear test (STT) was used to measure tear production. Results. SAR 1118 demonstrated concentration-dependent inhibition of Jurkat T-cell attachment, inhibition of lymphocyte activation, and release of inflammatory cytokines, particularly the Th1, Th2, and Th17 T-cell cytokines IFN-γ, IL-2, and IL-17F, respectively. Mean STT values increased from 3.4 mm during week 1 to 5.8 mm at week 12 (P < 0.025). No SAR 1118-related adverse events were observed. Conclusions. SAR 1118 appears to be an effective anti-inflammatory treatment for KCS. Additional studies are warranted to establish the efficacy of SAR 1118 for the treatment of KCS in humans.

Original languageEnglish (US)
Pages (from-to)3174-3180
Number of pages7
JournalInvestigative Ophthalmology and Visual Science
Volume52
Issue number6
DOIs
StatePublished - May 2011

Fingerprint

Keratoconjunctivitis Sicca
Lymphocyte Function-Associated Antigen-1
Dogs
Tears
Cytokines
Jurkat Cells
Intercellular Adhesion Molecule-1
T-Lymphocytes
Inflammation
SAR 1118
Th17 Cells
Lacrimal Apparatus
Interleukin-17
Ophthalmic Solutions
Lymphocyte Activation
Interleukin-2
Canidae
Blood Cells
Membrane Proteins
Anti-Inflammatory Agents

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience
  • Medicine(all)

Cite this

The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs. / Murphy, Christopher J; Bentley, Ellison; Miller, Paul E.; McIntyre, Kim; Leatherberry, Gary; Dubielzig, Richard; Giuliano, Elizabeth; Moore, Cecil P.; Phillips, Thomas E.; Smith, Peter B.; Prescott, Elizabeth; Miller, Jacqueline M.; Thomas, Peter; Scagliotti, Randall; Esson, Doug; Gadek, Tom; O'Neill, Charles A.

In: Investigative Ophthalmology and Visual Science, Vol. 52, No. 6, 05.2011, p. 3174-3180.

Research output: Contribution to journalArticle

Murphy, CJ, Bentley, E, Miller, PE, McIntyre, K, Leatherberry, G, Dubielzig, R, Giuliano, E, Moore, CP, Phillips, TE, Smith, PB, Prescott, E, Miller, JM, Thomas, P, Scagliotti, R, Esson, D, Gadek, T & O'Neill, CA 2011, 'The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs', Investigative Ophthalmology and Visual Science, vol. 52, no. 6, pp. 3174-3180. https://doi.org/10.1167/iovs.09-5078
Murphy, Christopher J ; Bentley, Ellison ; Miller, Paul E. ; McIntyre, Kim ; Leatherberry, Gary ; Dubielzig, Richard ; Giuliano, Elizabeth ; Moore, Cecil P. ; Phillips, Thomas E. ; Smith, Peter B. ; Prescott, Elizabeth ; Miller, Jacqueline M. ; Thomas, Peter ; Scagliotti, Randall ; Esson, Doug ; Gadek, Tom ; O'Neill, Charles A. / The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs. In: Investigative Ophthalmology and Visual Science. 2011 ; Vol. 52, No. 6. pp. 3174-3180.
@article{d8b5e7d66fd44ae68d87dc0fcfe8e19d,
title = "The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs",
abstract = "Purpose. Keratoconjunctivitis sicca (KCS) is characterized by inflammation and decreased production of tears containing increased levels of cytokines. The release occurs in the setting of conjunctival and lacrimal gland inflammation, potentially mediated by the interaction between lymphocyte function- associated antigen (LFA)-1, a cell surface protein found on lymphocytes, and its cognate ligand intercellular adhesion molecule (ICAM)-1. SAR 1118 is a novel LFA-1 antagonist and may be an effective therapeutic agent for the treatment of KCS. The following studies were performed to assess the in vitro activity of SAR 1118 and to evaluate the clinical efficacy of topical SAR 1118 for the treatment of idiopathic canine KCS. Method. Pharmacodynamics were assessed by measuring the ability of SAR 1118 to inhibit Jurkat T-cell binding with recombinant human ICAM-1 and to inhibit cytokine release from human peripheral blood mononuclear cells (PBMCs) stimulated by staphylococcal enterotoxin B. For the assessment of clinical efficacy, 10 dogs diagnosed with idiopathic KCS were treated with SAR 1118 1{\%} topical ophthalmic solution three times daily for 12 weeks. Schirmer's tear test (STT) was used to measure tear production. Results. SAR 1118 demonstrated concentration-dependent inhibition of Jurkat T-cell attachment, inhibition of lymphocyte activation, and release of inflammatory cytokines, particularly the Th1, Th2, and Th17 T-cell cytokines IFN-γ, IL-2, and IL-17F, respectively. Mean STT values increased from 3.4 mm during week 1 to 5.8 mm at week 12 (P < 0.025). No SAR 1118-related adverse events were observed. Conclusions. SAR 1118 appears to be an effective anti-inflammatory treatment for KCS. Additional studies are warranted to establish the efficacy of SAR 1118 for the treatment of KCS in humans.",
author = "Murphy, {Christopher J} and Ellison Bentley and Miller, {Paul E.} and Kim McIntyre and Gary Leatherberry and Richard Dubielzig and Elizabeth Giuliano and Moore, {Cecil P.} and Phillips, {Thomas E.} and Smith, {Peter B.} and Elizabeth Prescott and Miller, {Jacqueline M.} and Peter Thomas and Randall Scagliotti and Doug Esson and Tom Gadek and O'Neill, {Charles A.}",
year = "2011",
month = "5",
doi = "10.1167/iovs.09-5078",
language = "English (US)",
volume = "52",
pages = "3174--3180",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "6",

}

TY - JOUR

T1 - The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs

AU - Murphy, Christopher J

AU - Bentley, Ellison

AU - Miller, Paul E.

AU - McIntyre, Kim

AU - Leatherberry, Gary

AU - Dubielzig, Richard

AU - Giuliano, Elizabeth

AU - Moore, Cecil P.

AU - Phillips, Thomas E.

AU - Smith, Peter B.

AU - Prescott, Elizabeth

AU - Miller, Jacqueline M.

AU - Thomas, Peter

AU - Scagliotti, Randall

AU - Esson, Doug

AU - Gadek, Tom

AU - O'Neill, Charles A.

PY - 2011/5

Y1 - 2011/5

N2 - Purpose. Keratoconjunctivitis sicca (KCS) is characterized by inflammation and decreased production of tears containing increased levels of cytokines. The release occurs in the setting of conjunctival and lacrimal gland inflammation, potentially mediated by the interaction between lymphocyte function- associated antigen (LFA)-1, a cell surface protein found on lymphocytes, and its cognate ligand intercellular adhesion molecule (ICAM)-1. SAR 1118 is a novel LFA-1 antagonist and may be an effective therapeutic agent for the treatment of KCS. The following studies were performed to assess the in vitro activity of SAR 1118 and to evaluate the clinical efficacy of topical SAR 1118 for the treatment of idiopathic canine KCS. Method. Pharmacodynamics were assessed by measuring the ability of SAR 1118 to inhibit Jurkat T-cell binding with recombinant human ICAM-1 and to inhibit cytokine release from human peripheral blood mononuclear cells (PBMCs) stimulated by staphylococcal enterotoxin B. For the assessment of clinical efficacy, 10 dogs diagnosed with idiopathic KCS were treated with SAR 1118 1% topical ophthalmic solution three times daily for 12 weeks. Schirmer's tear test (STT) was used to measure tear production. Results. SAR 1118 demonstrated concentration-dependent inhibition of Jurkat T-cell attachment, inhibition of lymphocyte activation, and release of inflammatory cytokines, particularly the Th1, Th2, and Th17 T-cell cytokines IFN-γ, IL-2, and IL-17F, respectively. Mean STT values increased from 3.4 mm during week 1 to 5.8 mm at week 12 (P < 0.025). No SAR 1118-related adverse events were observed. Conclusions. SAR 1118 appears to be an effective anti-inflammatory treatment for KCS. Additional studies are warranted to establish the efficacy of SAR 1118 for the treatment of KCS in humans.

AB - Purpose. Keratoconjunctivitis sicca (KCS) is characterized by inflammation and decreased production of tears containing increased levels of cytokines. The release occurs in the setting of conjunctival and lacrimal gland inflammation, potentially mediated by the interaction between lymphocyte function- associated antigen (LFA)-1, a cell surface protein found on lymphocytes, and its cognate ligand intercellular adhesion molecule (ICAM)-1. SAR 1118 is a novel LFA-1 antagonist and may be an effective therapeutic agent for the treatment of KCS. The following studies were performed to assess the in vitro activity of SAR 1118 and to evaluate the clinical efficacy of topical SAR 1118 for the treatment of idiopathic canine KCS. Method. Pharmacodynamics were assessed by measuring the ability of SAR 1118 to inhibit Jurkat T-cell binding with recombinant human ICAM-1 and to inhibit cytokine release from human peripheral blood mononuclear cells (PBMCs) stimulated by staphylococcal enterotoxin B. For the assessment of clinical efficacy, 10 dogs diagnosed with idiopathic KCS were treated with SAR 1118 1% topical ophthalmic solution three times daily for 12 weeks. Schirmer's tear test (STT) was used to measure tear production. Results. SAR 1118 demonstrated concentration-dependent inhibition of Jurkat T-cell attachment, inhibition of lymphocyte activation, and release of inflammatory cytokines, particularly the Th1, Th2, and Th17 T-cell cytokines IFN-γ, IL-2, and IL-17F, respectively. Mean STT values increased from 3.4 mm during week 1 to 5.8 mm at week 12 (P < 0.025). No SAR 1118-related adverse events were observed. Conclusions. SAR 1118 appears to be an effective anti-inflammatory treatment for KCS. Additional studies are warranted to establish the efficacy of SAR 1118 for the treatment of KCS in humans.

UR - http://www.scopus.com/inward/record.url?scp=79960959962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960959962&partnerID=8YFLogxK

U2 - 10.1167/iovs.09-5078

DO - 10.1167/iovs.09-5078

M3 - Article

C2 - 21330663

AN - SCOPUS:79960959962

VL - 52

SP - 3174

EP - 3180

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 6

ER -